Article

Florida Cancer Specialists' Medical Oncologists Co-Author Analysis of Umbralisib in Lymphoid Malignancies

Three medical oncologists at Florida Cancer Specialists & Research Institute co-author a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

Fort Myers, FL – October 14, 2021–Florida Cancer Specialists & Research Institute (FCS) director of Clinical Research, Gustavo Fonseca, MD, FACP, director of Drug Development, Manish Patel, MD, and James Reeves, MD, a member of the FCS clinical research team, participated in a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

The study, “Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies,” was recently published online in Blood Advances.

Low rates of immune-mediated toxicities were observed with umbralisib and no cumulative toxicities were reported. The analysis concluded, “The favorable long-term tolerability profile and low rates of immune-mediated toxicities support the potential use of umbralisib for the benefit of a broad population of patients with lymphoid malignancies.”

Learn more.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Mansi Shah, MD
Dr Ibrahim Aldoss
Mansi Shah, MD
Dr John Mascarenhas
Merrill H. Stewart, MD
Dr John Mascarenhas
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo